Phase 4 Hypertension Trial, Recruiting NCT07247058 Sponsor: Johns Hopkins University Condition: Hypertension
Back to Hypertension

Phase 4 Hypertension Trial, Recruiting

NCT07247058
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been found to have a condition called mild autonomous cortisol secretion (MACS), which means the body produces slightly too much of a hormone called cortisol — confirmed by a specific blood test after taking a small dose of a medication called dexamethasone
  • People who have a non-cancerous growth on one of their adrenal glands, confirmed by a CT or MRI scan
  • People who are willing and able to give formal consent to take part
  • People who are willing to attend study-related appointments, including a bone density scan (DEXA) and blood or laboratory tests

Who may not be able to join:

  • People who have already been diagnosed with Cushing's syndrome or a more serious form of excess cortisol production
  • People who are currently taking, or have taken in the past 3 months, steroid medications (glucocorticoids) or certain other medications that affect cortisol levels, such as ketoconazole or metyrapone
  • People with severe liver problems or serious kidney failure
  • People who are pregnant or breastfeeding
  • People who have a known allergy to, or medical reason to avoid, the study drug osilodrostat (also known as Isturisa)
  • People who have taken part in another interventional clinical trial within the past 30 days
  • People with a medical or mental health condition that the trial doctor believes could affect their safety or ability to take part (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Amir Hamrahian, MD, Johns Hopkins University

Phone: 667-208-8367

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
2 February 2026
Est. completion
1 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in fasting glucose, HbA1c; Change in bone mineral density (g/cm²); Change in body weight (kg) from baseline during Isturisa treatment; Change in lipid profile from baseline during Isturisa treatment; Change in body composition (kg)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov